A
Alain Saraux
Researcher at French Institute of Health and Medical Research
Publications - 548
Citations - 15651
Alain Saraux is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Medicine & Rheumatoid arthritis. The author has an hindex of 62, co-authored 483 publications receiving 13485 citations. Previous affiliations of Alain Saraux include University of Western Brittany & European University of Brittany.
Papers
More filters
Journal ArticleDOI
The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis
TL;DR: Among environmental factors implicated in the development of RA, smoking shows the strongest association with RA susceptibility and is also linked to worse outcomes, as well as the genetic and environmental risk factors associated with RA.
Journal ArticleDOI
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome
Raphaèle Seror,Philippe Ravaud,Xavier Mariette,Xavier Mariette,Hendrika Bootsma,Elke Theander,Arne Hansen,Manel Ramos-Casals,Thomas Doerner,Stefano Bombardieri,Eric Hachulla,Johan G. Brun,Aike A. Kruize,Sonja Praprotnik,Matija Tomšič,Jacques-Eric Gottenberg,Valérie Devauchelle,Salvatore deVita,C. Vollenweider,Thomas Mandl,Athanasios G. Tzioufas,Steven E. Carsons,Alain Saraux,Nurhan Sutcliffe,Claudio Vitali,Simon J Bowman +25 more
TL;DR: The EULAR SS Patient Reported Index is a very simple index designed to measure patients' symptoms in primary SS and has good construct validity and is well correlated with SSI and PROFAD.
Journal ArticleDOI
BAFF overexpression is associated with autoantibody production in autoimmune diseases.
Jacques-Olivier Pers,Capucine Daridon,Valérie Devauchelle,Sandrine Jousse,Alain Saraux,Christophe Jamin,Pierre Youinou +6 more
TL;DR: The data suggest that BAFF is influential in driving antibody production rather than activation of the B lymphocytes in autoimmune diseases, as well as with the presence of autoantibodies.
Journal ArticleDOI
Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).
Valérie Devauchelle-Pensec,Y.L. Pennec,Johanne Morvan,Jacques-Olivier Pers,Capucine Daridon,Sandrine Jousse-Joulin,Anne Roudaut,Christophe Jamin,Yves Renaudineau,Isabelle Quintin Roué,Béatrice Cochener,Pierre Youinou,Alain Saraux +12 more
TL;DR: Low-dose rituximab infusions induced a rapid depletion of B cells in the blood and SG and could improve primary Sjögren's syndrome, and controlled studies are needed.
Journal ArticleDOI
Treatment of Primary Sjögren Syndrome With Rituximab: A Randomized Trial
Valérie Devauchelle-Pensec,Xavier Mariette,Sandrine Jousse-Joulin,Jean-Marie Berthelot,Aleth Perdriger,Xavier Puéchal,Véronique Le Guern,Jean Sibilia,Jacques-Eric Gottenberg,Laurent Chiche,Eric Hachulla,Pierre Yves Hatron,Vincent Goëb,Gilles Hayem,Jacques Morel,Charles Zarnitsky,Jean Jacques Dubost,Jacques-Olivier Pers,Emmanuel Nowak,Alain Saraux +19 more
TL;DR: This multicenter, double-blind, placebo-controlled, randomized trial found that rituximab alleviated some symptoms at week 6 but did not alleviate symptoms or improve global activity score at month 6 in adults with recent-onset or systemic pSS.